Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corifollitropin alfa plus hCG in adult men with hypogonadotropic hypogonadism and persistent azoospermia
2012-001258-25Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of corifollitropin alfa and human chorionic gonadotropin in hypogonadotropic hypogonadism (HH), sponsored by Merck & Co. Primary endpoints: Change from baseline to Week 52 in log-transformed testicular volume and Safety and tolerability. Started Jul 2012; status: completed.
02
Drugs
corifollitropin alfahuman chorionic gonadotropin
03
Conditions
hypogonadotropic hypogonadism (HH)
Beyond the preview
Go deeper on 2012-001258-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001258-25.